Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00294723 · ClinicalTrials.gov registry record · Phase 3
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 746
- Enrollment target
NCT00294723: Clinical Trial Phase 3 study, sponsored by Novo Nordisk A/S.
NCT00294723 is a Phase 3 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 746 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00294723, a Phase 3 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 746 participants
- Enrollment target
Study Summary
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open-label extension (week 104) followed by an additional 156-week continued open-label extension. The total duration of the treatment period is planned to be 260 weeks (5 years).
Primary Outcome
Percentage point change in Glycosylated Haemoglobin A1c (HbA1c) from baseline (week 0) to 52 weeks (end of double-blind period)
Interventions
- DRUG placebo
- DRUG liraglutide
- DRUG glimepiride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 746 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Why NCT00294723 stopped before completion
NCT00294723 is an interventional study that assigns participants to a tested intervention. The registered 746 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00294723 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00294723 about?
NCT00294723 is a clinical study titled "To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c". This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes. The trial is a 52-week randomised, double-blind trial period plus a 52-week open...
What is the current status of trial NCT00294723?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 746 participants. The study started on 2006-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00294723?
The interventions under investigation include: placebo (DRUG), liraglutide (DRUG), glimepiride (DRUG).
Who is sponsoring clinical trial NCT00294723?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00294723's enrollment target sits among peer trials
746 474th of 2000 higher than 1,526 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia